Treatment of Major Depressive Disorder with Synbiotics

Authors

Katherine M. Lopez, DMSc studentFollow

Specialty

General Medicine

Advisor

Dr. Lawrence Herman

Abstract

ABSTRACT

Purpose: The manuscript aims to review the treatment of Major Depressive Disorder (MDD) and associated symptoms with probiotics and prebiotics known together as synbiotics through the bidirectional Gut-Brain-Axis (GBA) and Central Nervous System (CNS) pathway.

Method: A literature search from PubMed was investigated for depression, probiotics, and prebiotics as an alternative treatment for depression by the Gut-Brain Axis (GBA); a total of ten relevant articles were used for this manuscript.

Results: The results from the search determined that an altered GBA is related to MDD, and regulation of the gut microbiome can lead to a relief of symptoms of depression.

Conclusion: Statistics for MDD show that only 36.9% will receive treatment for mental health illnesses.¹ Depression is a mental health disorder that requires medical attention and, if left untreated, can be detrimental and debilitating for individuals ages 15 to 44.² The Gut-Brain Axis (GBA) and the Central Nervous System (CNS) operates neural and endocrine pathways to collaborate with the gut, which is the communication between the brain and the gut.³ Synbiotics regulate the gut for healthy and well-balanced bacteria that may also help treat symptoms of anxiety and depression. Evolving gut microbiome study from synbiotics may provide possible treatments and preventative measures for depressive and anxiety disorders.³ Studies and data support the Gut-Brain-Axis (GBA) correlation and its association to depression.

Recommended Citation

Lopez KM. Treatment of Major Depressive Disorder with Synbiotics. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2022; 4(2).